Participant flow

A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting · Source last updated 2021-06-11

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   neratinib 240 mg orally, once daily with food, continuously in 21 day cycles, and capecitabine 1500 mg/m\^2 daily in 2 evenly divided doses, orally with water within 30 minutes after a meal, taken on days 1 to 14 of each 21 day cycle.

   id

   FG000

   title

   Neratinib Plus Capecitabine

2. description

   lapatinib 1250 mg orally, once daily, continuously in 21 day cycles, and capecitabine 2000 mg/m\^2 daily in 2 evenly divided doses, orally with water within 30 minutes after a meal, taken on days 1 to 14 of each 21 day cycle.

   id

   FG001

   title

   Lapatinib Plus Capecitabine

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         212

      2. group Id

         FG001

         num Subjects

         240

      type

      Death

   2. reasons

      1. group Id

         FG000

         num Subjects

         12

      2. group Id

         FG001

         num Subjects

         10

      type

      Withdrawal by Subject

   3. reasons

      1. group Id

         FG000

         num Subjects

         3

      2. group Id

         FG001

         num Subjects

         0

      type

      Lost to Follow-up

   4. reasons

      1. group Id

         FG000

         num Subjects

         79

      2. group Id

         FG001

         num Subjects

         64

      type

      Discontinuation of study by sponsor

   5. reasons

      1. group Id

         FG000

         num Subjects

         1

      2. group Id

         FG001

         num Subjects

         0

      type

      Randomized in Error

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         307

      2. group Id

         FG001

         num Subjects

         314

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         303

      2. group Id

         FG001

         num Subjects

         311

      type

      Received Treatment

   3. achievements

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         0

      type

      COMPLETED

   4. achievements

      1. group Id

         FG000

         num Subjects

         307

      2. group Id

         FG001

         num Subjects

         314

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice